3.4.21.91: Flavivirin
This is an abbreviated version!
For detailed information about Flavivirin, go to the full flat file.
Word Map on EC 3.4.21.91
-
3.4.21.91
-
polyprotein
-
viruses
-
ns4a
-
replicons
-
west
-
ribavirin
-
anti-hcv
-
direct-acting
-
virologic
-
cirrhosis
-
flaviviral
-
boceprevir
-
flaviviruses
-
encephalitis
-
pegylated
-
flaviviridae
-
telaprevir
-
subgenomic
-
rna-dependent
-
unwind
-
mosquito-borne
-
asunaprevir
-
resistance-associated
-
daclatasvir
-
simeprevir
-
hcv-infected
-
coronaviruses
-
anti-dengue
-
ntpase
-
peptidomimetic
-
nonnucleoside
-
hcv-specific
-
macrodomains
-
drug development
-
treatment-naive
-
peginterferon
-
replicase
-
quasispecies
-
interferon-free
-
trans-cleavage
-
alphavirus
-
positive-stranded
-
sofosbuvir
-
analysis
-
molecular biology
-
rna-stimulated
-
medicine
-
hcv-1b
-
synthesis
-
gt1
- 3.4.21.91
- polyprotein
- viruses
- ns4a
-
replicons
-
west
- ribavirin
-
anti-hcv
-
direct-acting
-
virologic
-
cirrhosis
-
flaviviral
- boceprevir
- flaviviruses
- encephalitis
-
pegylated
- flaviviridae
- telaprevir
-
subgenomic
-
rna-dependent
-
unwind
-
mosquito-borne
- asunaprevir
-
resistance-associated
-
daclatasvir
- simeprevir
-
hcv-infected
- coronaviruses
-
anti-dengue
- ntpase
-
peptidomimetic
-
nonnucleoside
-
hcv-specific
-
macrodomains
- drug development
-
treatment-naive
-
peginterferon
-
replicase
-
quasispecies
-
interferon-free
-
trans-cleavage
- alphavirus
-
positive-stranded
- sofosbuvir
- analysis
- molecular biology
-
rna-stimulated
- medicine
-
hcv-1b
- synthesis
- gt1
Reaction
Selective hydrolysis of -Xaa-Xaa-/-Yaa- bonds in which each of the Xaa can be either Arg or Lys and Yaa can be either Ser or Ala =
Synonyms
Dengue NS2b-NS3 protease, Dengue NS3 protease, dengue virus non-structural protein 3, dengue virus NS2B-NS3 protease, dengue virus protease, dengue virus serotype 2 protease, DENV NS2B-NS3, DENV-2 NS2B-NS3 protease, DENV2 NS2BNS3pro, DV2 NS2B/NS3pro, flavivirus NS2B-NS3 protease, non-structural protein 3 serine protease, non-structural protein NS2B-NS3 protease, nonstructural protein 3, NS2-3 protease, NS2B-3 proteinase, NS2B-NS3 complex, NS2B-NS3 protease, NS2B-NS3 protease-helicase, NS2B-NS3 proteinase, NS2B-NS3 proteolytic complex, NS2B-NS3 serine protease, NS2B-NS3 serine proteinase, NS2B-NS3(pro)teinase, NS2b-NS3-protease, NS2B-NS3p, NS2B-NS3pro, NS2B/3 protease, NS2B/NS3, NS2B/NS3 complex, NS2B/NS3 protease, NS2B/NS3 protease complex, NS2B/NS3 proteinase, NS2B/NS3 serine protease, NS2B/NS3pro serine protease, NS2B18NS3, NS2BNS3(pro)tease, NS3, NS3 protease, NS3 proteinase, NS3 serine protease, NS3pro, two-component NS2B-NS3 protease, viral serine protease NS2B/NS3, WNV NS2B-NS3, Yellow fever virus (flavivirus) protease, yellow fever virus NS2B-NS3-181 protease, YFV NS2B/NS3 protease, Zika protease, Zika virus NS2B-NS3 protease, ZIKV NS2B/NS3 protease, ZIKV protease
ECTree
3.4.21.91 FlavivirinAdvanced search results
results (
results (Application
Application on EC 3.4.21.91 - Flavivirin
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
top
APPLICATION 
ORGANISM
UNIPROT
COMMENTARY 
LITERATURE
analysis
drug development
medicine
-
to validate NS2B as a potential target in allosteric inhibitor development, a cNS2B specific human monoclonal antibody (3F10) is used. 3F10 disrupts the interaction between cNS2B and NS3 in vitro and reduces DENV viral replication in HEK293 cells
molecular biology
-
it is demonstrated that the WNV NS2B/NS3pro-hel is an active endoproteolytic enzyme at the ER membrane and the in-cell selectivity profiling of the membrane-anchored flaviviral protease is reported
synthesis
-
expression and purification of a natural form of DENV protease containing the full-length NS2B protein and the protease domain of NS3. The protease is expressed in Escherichia coli and purified in detergent micelles necessary for its folding. This purified protein is active in detergent micelles such as lyso-myristoyl phosphatidylcholine
analysis
-
NS2B-NS3pro K48A mutant construct is well suited for follow-up purification and structural and drug design studies
analysis
-
two sets of prediction approaches. Secondary structure prediction performed using available structure prediction servers. A second approach makes use of the information on the secondary structures extracted from structure prediction servers, threading techniques and DSSP database of some of the templates used in the threading techniques. Consensus on the one-dimensional secondary structure of Dengue virus type 2 protease obtained from each approach and evaluated against data from the recently crystallised Dengue virus type 2 NS2B/NS3 obtained from the Protein Data Bank. The second approach shows higher accuracy compared to the use of prediction servers only and thus is applicable to the initial stage of structural studies of proteins with low amino acid sequence homology against other available proteins in the Protein Data Bank
drug development
-
characteristics of Yellow fever virus protease are very similar to those reported for dengue and West Nile virus proteases, and suggest that pan-flavivirus NS3 protease drugs may be developed for flaviviral diseases
drug development
-
proteolysis through formation of a composite active site in NS2-3 protease occurs in the context of the viral polyprotein expressed in mammalian cells. This offers new opportunities for antiviral drug design
drug development
-
switched cleavage preferences of West Nile virus NS2B-NS3(pro)teinase may provide valuable data for the design of optimized substrates and substrate-based selective inhibitors of flaviviral proteinases
drug development
-
unique cleavage preferences of the Dengue virus protease promise novelty for the design of potent inhibitors that may be selective for the flaviviral proteases over proteases of the host cell and thus provide a solid base for follow-on structural and functional studies
drug development
-
unique cleavage preferences of the West Nile virus protease promise novelty for the design of potent inhibitors that may be selective for the flaviviral proteases over proteases of the host cell and thus provide a solid base for follow-on structural and functional studies
drug development
useful for the development of specific allosteric inhibitors designed to interfere with the productive interactions of NS2B with NS3pro
drug development
flavivirus NS2B-NS3 protease-helicase is a target for antiviral drug development
drug development
flavivirus NS2B-NS3 protease-helicase is a target for antiviral drug development
drug development
flavivirus NS2B-NS3 protease-helicase is a target for antiviral drug development
drug development
flavivirus NS2B-NS3 protease-helicase is a target for antiviral drug development
drug development
flavivirus NS2B-NS3 protease-helicase is a target for antiviral drug development
drug development
flavivirus NS2B-NS3 protease-helicase is a target for antiviral drug development
drug development
flavivirus NS2B-NS3 protease-helicase is a target for antiviral drug development
drug development
flavivirus NS2B-NS3 protease-helicase is a target for antiviral drug development
drug development
flavivirus NS2B-NS3 protease-helicase is a target for antiviral drug development
drug development
flavivirus NS2B-NS3 protease-helicase is a target for antiviral drug development
drug development
-
the dengue virus NS2B-NS3 protease (NS2B-NS3p) is an important antiviral target for drug development
drug development
-
the enzyme is a target for the development of structure-based antiviral drugs against ZIKV and related pathogenic flaviviruses
drug development
-
the viral serine protease NS2B/NS3 is an attractive target for the development of anti-WNV agents
drug development
Dengue virus type 2 Thailand/16681/1984
-
flavivirus NS2B-NS3 protease-helicase is a target for antiviral drug development
-
drug development
-
flavivirus NS2B-NS3 protease-helicase is a target for antiviral drug development
-
drug development
Yellow fever virus 17D vaccine
-
flavivirus NS2B-NS3 protease-helicase is a target for antiviral drug development
-
drug development
-
flavivirus NS2B-NS3 protease-helicase is a target for antiviral drug development
-
drug development
-
the essential enzyme is a target for drug design
-
drug development
Dengue virus type 2 16681
-
unique cleavage preferences of the Dengue virus protease promise novelty for the design of potent inhibitors that may be selective for the flaviviral proteases over proteases of the host cell and thus provide a solid base for follow-on structural and functional studies
-
drug development
dengue virus type I Nauru/West Pac/1974
-
flavivirus NS2B-NS3 protease-helicase is a target for antiviral drug development
-
drug development
-
unique cleavage preferences of the West Nile virus protease promise novelty for the design of potent inhibitors that may be selective for the flaviviral proteases over proteases of the host cell and thus provide a solid base for follow-on structural and functional studies
-
drug development
-
useful for the development of specific allosteric inhibitors designed to interfere with the productive interactions of NS2B with NS3pro
-
drug development
-
flavivirus NS2B-NS3 protease-helicase is a target for antiviral drug development
-
drug development
-
flavivirus NS2B-NS3 protease-helicase is a target for antiviral drug development
-
drug development
Murray Valley encephalitis virus MVE-1-51
-
flavivirus NS2B-NS3 protease-helicase is a target for antiviral drug development
-
